CORAL GABLES, Fla.
/PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced that
Patrick J. McEnany
, Catalyst's Chief Executive Officer, will be making a presentation at the BioNetwork East 2010 Conference to be held
March 15th through March 17th
at the Eden Roc Resort and Spa on
. Catalyst will present a Corporate Overview, including its development plans for CPP-109 and CPP-115. Further, the Company reported that its presentation materials from the conference will be posted on
on the Company's website,
, under "Events and Presentations."
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. The Company has obtained from Brookhaven National Laboratory an exclusive license for nine patents in
the United States
relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also in-licensed worldwide rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. CPP-109, Catalyst's version of vigabatrin, has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. Catalyst has also recently in-licensed worldwide rights to another patented drug, CPP-115, from
. The Company intends to pursue development of CPP-115 for several indications, including epilepsy and drug addiction. For more information about the Company, go to
SOURCE Catalyst Pharmaceutical Partners, Inc.